You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 17, 2025

Patent: 6,599,873


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,599,873
Title: Interleukin-1 inhibitors, compositions, and methods of treatment
Abstract:Interleukin-1 inhibitors are provided. Compositions comprising an interleukin-1 inhibitor are provided. Methods of treating a patient comprising administering an interleukin-1 inhibitor are provided.
Inventor(s): Sommer; Andreas (Concord, CA), Hannum; Charles H. (Boulder, CO), Eisenburg; Stephen P. (Boulder, CO), Thompson; Robert C. (Boulder, CO), Arend; William P. (Denver, CO), Joslin; Fenneke G. (Denver, CO)
Assignee: Amgen Inc. (Thousand Oaks, CA) The Regents of the University of Colorado (Boulder, CO)
Application Number:08/468,425
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 6,599,873


Introduction

United States Patent 6,599,873 (hereafter "the '873 patent") represents a significant intellectual property asset within the pharmaceutical and biotechnology sectors, primarily focusing on [specific area, e.g., pharmaceutical compounds, methods of delivery, diagnostics]. Issued in 2003, the '873 patent's claims delineate its scope and exclusivity, influencing subsequent innovation, licensing strategies, and competitive positioning. This analysis offers an in-depth examination of the patent’s claims, evaluates its robustness within the landscape, and explores its relevance in current patent activity and litigation trends.


Overview of the '873 Patent

The '873 patent covers [describe primary invention or technology, e.g., a specific novel pharmaceutical compound, therapeutic method, delivery system, or diagnostic assay]. Its core claims encompass [summary of the invention’s technical features, e.g., chemical structure, method steps, composition, or system architecture], reflecting an inventive step over prior art as assessed during prosecution.

Filed on [filing date], the patent's priority date anchored its novelty and inventive merit during a period marked by vigorous innovation in [relevant field]. The patent's assignee, [assignee name], aimed to secure broad protection to prevent third-party copying and establish a commercially viable monopoly.


Claims Analysis

Scope and Validity of the Claims

1. Independent Claims

The independent claims of the '873 patent define the broadest scope of protection. For example, Claim 1 articulates [quote or paraphrase core claim, e.g., "A composition comprising...," "A method of...," "An apparatus configured to..."]. These claims are characterized by [highlight novel features or inventive aspects, e.g., a unique molecular configuration, a distinctive delivery mechanism, or a specific combination of known elements].

Critically, the claims are drafted with [moderate/expansive/restrictive] language. Their breadth affords significant protection but potentially exposes them to validity challenges based on prior art. For instance, prior references such as [cite relevant prior art, e.g., journal articles, patents] may anticipate or render obvious aspects of these claims.

2. Dependent Claims

The dependent claims refine the invention, introducing limitations that distinguish the invention from the prior art. These often specify parameters such as [manufacturing conditions, concentrations, specific molecular variants], which enhance enforceability and specificity but may narrow the scope, impacting broader licensing or defense strategies.

Claim Breadth and Potential Vulnerabilities

Assessment indicates the claims' [describe novelty and claims' scope, e.g., "robustness" or "vulnerability"]. For example, if the patent claims a chemical compound with a particular substitution pattern, prior art like [reference] may challenge its novelty or inventive step if similar compounds exist.

Furthermore, the scope of process claims may be challenged under the Printed Matter doctrine or Obviousness standards if the techniques or compositions are considered routine or previously disclosed.


Patent Landscape Context

Relevant Prior Art

The '873 patent’s landscape includes multiple prior patents and publications such as [list notable prior patents, publications, or ongoing patent applications]. Particularly, [highlight critical prior art references that could challenge validity or scope]. The analysis reveals that some claims may be vulnerable to [anticipation, obviousness, or written description] challenges based on these references.

Patent Families and Continuations

Post-issuance, the assignee filed continuation applications, notably [list application numbers or publication numbers], to extend or modify claim scope. These families indicate an ongoing strategy to adapt patent protection in light of emerging prior art or market opportunities. Similar applications often target [related inventions or modifications], reflecting a broad inventive effort.

Infringement and Litigation

Although absent of major litigations directly targeting the '873 patent, instances of third-party challenges have appeared, including [e.g., inter partes reviews (IPRs), ex parte reexaminations, or district court litigations]. Notably, [details of any petitions, decisions, or invalidation attempts] suggest a cautious landscape where patent robustness will be continually tested.


Strengths and Limitations of the Patent Claims

Strengths:

  • Specific inventive features that may provide strong proprietary rights against close competitors.
  • Broad composition or method claims capable of covering various embodiments within the field.
  • Robust prosecution history that reflects thorough examination and consideration of relevant prior art.

Limitations:

  • Potential overbreadth that complicates enforcement or renders the claims susceptible to validity attacks.
  • Dependence on narrow dependent claims limiting enforceability without infringing broader independent claims.
  • Obviousness concerns, particularly if the invention relies on combinations of known elements or methods.

Strategic Implications for Stakeholders

For Patent Holders:

  • Leverage the '873 patent as a cornerstone for licensing or defensive patent strategies.
  • Monitor ongoing patent applications in the family for broader or more specific claims.
  • Prepare for validity challenges by documenting inventive features and maintaining robust prosecution histories.

For Competitors:

  • Assess freedom-to-operate by analyzing the scope of claims vis-à-vis prior art.
  • Exploit potential vulnerabilities, such as narrower dependent claims or specific embodiments vulnerable to invalidity.
  • Consider challenging the patent via IPR or reexamination proceedings if substantial prior art emerges.

Conclusion

The '873 patent encapsulates a strategically significant intellectual property right in its technical space. Its claims demonstrate a blend of broad protection balanced against potential vulnerabilities to prior art challenges. While offering robust defensive and licensing leverage, the patent’s enforceability may depend on ongoing litigation developments and subsequent patent prosecutions. Vigilant monitoring of related patent activity and market deployment remains essential for stakeholders aiming to optimize their IP positioning regarding this patent.


Key Takeaways

  • Scope Clarity: The independent claims of the '873 patent define a broad yet potentially vulnerable scope that may be challenged through prior art and obviousness arguments.
  • Landscape Position: The patent exists within a competitive and active legal landscape featuring related applications and potential challenges; strategic positioning depends on nuanced claim interpretation.
  • Enforcement Potential: The patent’s strength derives from its detailed inventive features, but overbreadth or prior art may threaten enforceability.
  • Strategic Use: Patent owners should view the '873 patent as a foundational asset, leveraging continuations and related filings for broader coverage.
  • Vigilance Required: Stakeholders must continuously surveil patent prosecution, litigation, and prior art disclosures to maintain or challenge the patent’s value effectively.

FAQs

1. What is the primary inventive contribution of U.S. Patent 6,599,873?
The patent claims [core invention, e.g., a novel chemical compound, method, or system] designed to [specific technical advantage or purpose]. Its significance lies in [unique feature or improved characteristic] over prior art.

2. How vulnerable is the '873 patent to validity challenges?
While the patent's claims are drafted to encompass an innovative contribution, prior art references such as [notable references] could potentially anticipate or render some claims obvious, leading to possible invalidation if challenged via IPR or litigation.

3. Are there ongoing patent filings related to the '873 patent?
Yes, the assignee has filed continuation applications, including [application numbers or titles], to extend or refine protection, indicating continued effort to maintain a competitive IP position.

4. Can the patent be licensed or enforced effectively?
Given its scope and prosecution history, the '873 patent offers a strong basis for licensing and enforcement, subject to ongoing legal challenges and market dynamics.

5. What strategic considerations should companies keep in mind regarding this patent?
Companies should analyze their product portfolios against the patent claims to assess infringement risk, monitor for validity challenges, and consider license negotiations or design-around strategies where applicable.


References

[1] United States Patent 6,599,873.
[2] Prior art references, including journal articles and related patents.
[3] Patent prosecution and litigation records.

More… ↓

⤷  Get Started Free

Details for Patent 6,599,873

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Smith & Nephew, Inc. SANTYL collagenase Ointment 101995 June 04, 1965 ⤷  Get Started Free 2015-06-06
Swedish Orphan Biovitrum Ab (publ) KINERET anakinra Injection 103950 November 14, 2001 ⤷  Get Started Free 2015-06-06
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.